Ivabradine (Procoralan) has received a new licence based on data from the SHifT trial; the largest ever morbimortality study of treatments for chronic heart failure involving more than 6,000 people. Data from the trial demonstrated that patients with chronic systolic heart failure and a heart rate over 70 beats per minute had an 18% reduction (ARR = 4.2% p<0.0001) in the composite primary endpoint of CV death and hospitalisation due to heart failure. Ivabradine is indicated in patients in NYHA II to IV with systolic dysfunction, in patients in sinus rhythm with heart rate >75 bpm, in combination with standard therapy including beta-blocker therapy or when beta-blocker therapy is contraindicated or not tolerated. Within the new indication, ivabradine reduced the risk of death from heart failure by 39% (ARR 2.2% p=0.0006), the risk of death from all types of cardiovascular disease by 17% (ARR 2.6% p=0.0166) and the risk of death from all causes by 17% (ARR 2.8% p=0.0109). In addition, ivabradine significantly reduced the risk of heart failure patients requiring hospitalisation by 30% (ARR = 6.3% p<0.0001) and improved the quality of life of people living with the disease. Ivabradine could now provide additional protection for patients when the best attempts to up-titrate the standard NICE recommended heart failure treatments, including ACE inhibitors and beta-blockers, have not provided sufficient relief.